Skip to main content

Table 4 Comparison of metabolites concentrations and enzyme activities based on fatty acid ratios between the final and the baseline status (Final vs. Baseline) in group 2 (not meeting the NAFLD criteria at baseline but meeting them during the follow-up)

From: Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

Metabolites and enzyme activities

Paired Student’s t-test (p-value)

log2 (fold change)

Steroids

9.05E-03

−0.38

Saturated fatty acids

1.64E-02

−0.42

Primary fatty amides

4.26E-02

−0.34

N-Acyl ethanolamines

2.39E-02

−0.23

1-Monoacylglycerophosphocholine

2.78E-02

−0.16

Monoacylglycerophosphocholine

4.00E-02

−0.14

Desaturase (MUFA + PUFA/SFA)

7.55E-04

0.39

MAPC/MAPE

8.21E-04

−0.34

LPC/LPE

5.71E-04

−0.31

(NEFA) n-6 /n-3

3.69E-02

−0.27

De novo lipogenesis (16:0/18:2n-6)

1.72E-03

−0.48

Stearoyl-CoA desaturase 1 (18:1n-9/18:0)

1.79E-02

−0.33

Elongase-6 (18:0/16:0)

3.13E-02

0.70

Delta-6- desaturase (18:3n-6/18:2n-6)

2.39E-03

−0.48

Delta-6- desaturase (18:3/18:2)

7.64E-03

−0.39

Delta-6- desaturase(18:4n-3/18:3n-3)

1.21E-02

2.72

Stearoyl-CoA desaturase 1 (16:1n-7/16:0)

1.11E-02

0.11

18:1/18:0

2.69E-02

−0.12

PUFA/MUFA

1.50E-02

0.25

  1. log2 (fold-change) and p-values follows the criterion of heatmap figure
  2. Abbreviations: SFA saturated fatty acids, PUFA polyunsaturated fatty acids, MUFA monounsaturated fatty acids, MAPC Monoacylglycerophosphocholine, MAPE Monoacylglycerophosphoethanolamine, LPC lysophosphatidylcholine, LPE lysophosphatidylethanolamine, NEFA non esterified fatty acids